Page last updated: 2024-12-11
bacopaside ii
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bacopaside II: isolated from Bacopa monniera Wettst; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Bacopa | genus | A plant genus of the family Plantaginaceae. Members contain bacopaside, bacopasaponins and other dammarane type jujubogenins.[MeSH] | Plantaginaceae | A plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9876264 |
MeSH ID | M0408599 |
Synonyms (15)
Synonym |
---|
bacopaside ii |
3-o-alpha-l-arabinofuranosyl-(1-2)-(beta-d-glucopyranosyl (1-3))-beta-d-glucopyranosyl pseudo-jujubogenin |
382146-66-9 |
unii-zo6l404y9t |
bacopaside ii (constituent of bacopa) [dsc] |
ZO6L404Y9T , |
bacopaside ii, (-)- |
HY-N6016 |
CS-0032179 |
Q27295806 |
bacopaside ii(p) |
XB177549 |
AS-82707 |
DTXSID201347350 |
AKOS040760287 |
Research Excerpts
Overview
Bacopaside II is a major component of Bacopa monnieri. We studied its inhibitory effects and binding affinity towards the MARK4.
Excerpt | Reference | Relevance |
---|---|---|
"Bacopaside II is a major component of Bacopa monnieri; thus, we studied its inhibitory effects and binding affinity towards the MARK4." | ( Investigating MARK4 inhibitory potential of Bacopaside II: Targeting Alzheimer's disease. Alam, A; Anwar, S; Azhar, MK; Fatima, H; Hasan, GM; Hassan, MI; Islam, A; Kaur, P; Mohammad, T, 2023) | 1.89 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.46) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (8.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |